方法：中重度干眼患者40例随机分成试验组和对照组，每组各20例。试验组用玻璃酸钠滴眼液(3g/L)、对照组玻璃酸钠滴眼液(1g/L)联合重组人表皮生长因子滴眼液治疗，治疗前和治疗2wk后，通过症状评分、眼表疾病指数(OSDI)评分、泪膜破裂时间(BUT)、泪液分泌试验(Schirmer Ⅰ test，SⅠt)、角膜荧光素染色评分(FL)等评价两组疗效。

结果：治疗前，两组各项指标差异均无统计学意义。治疗2wk后，除SⅠt外，两组的其他指标和治疗前相比，差异均有统计学意义； 两组间相比，除症状评分和OSDI差异有统计学意义，余无统计学差异。

结论：高浓度玻璃酸钠滴眼液治疗中重度干眼，能有效缓解眼部不适症状，提高患者生存质量。

METHODS: Forty moderate to severe dry eye patients were included in the study according to the diagnosis criteria and randomized into two groups. The patients of the trial group received topical administration of high concentration sodium hyaluronate(3g/L), and those of the control group received sodium hyaluronate(1g/L)plus recombinant human epidermal growth factor. The dry eye symptom scores, ocular surface disease index(OSDI)scores, tear film break-up time(BUT), Schirmer Ⅰ test and corneal fluorescein staining score were evaluated.All the indexes were compared between the two groups 2wk before and after treatment.

RESULTS: There were no significant differences of the indicators between the two groups before treatment. After 2wk treatment, the differences were statistically significant compared to former except for the Schirmer Ⅰ test. Compared with the control group, the symptom scores and the OSDI scores were lowered. No significant differences were found in the other indicators between these two groups.

CONCLUSION: Topical usage of highconcentrations of sodium hyaluronate(3g/L)is beneficial for remitting the ocular symptoms in moderate to severe dry eyes, and also improve the quality of life of patients.